Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

GSK-923295 development continues in vivo and in phase I

Nov. 10, 2008

Phase III study shows Tarceva improves progression-free survival in NSCLC

Nov. 7, 2008

BTG licenses novel anticancer compound BGC-945 to Onyx

Nov. 7, 2008

Poniard presents top-line results from phase I oral picoplatin trial

Nov. 7, 2008

IMC-3G3 well tolerated in phase I advanced solid tumor study

Nov. 7, 2008

Inhibitors of JAK2 V617F mutation developed at SGX Pharmaceuticals

Nov. 7, 2008

Preliminary data reported for ANG-1005 in solid tumors, brain metastases and malignant glioma

Nov. 6, 2008

Pegylated docetaxel demonstrates improved efficacy in xenograft models

Nov. 6, 2008

Anticancer VEGFR/PDGFR tyrosine kinase inhibitor TAK-593 profiled

Nov. 6, 2008

First clinical data on TH-302 released

Nov. 6, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...